L&P Client Horizon Therapeutics Prevails in Federal Circuit Appeal Preserving IPR Victories

The U.S. Court of Appeals for the Federal Circuit today issued a judgment summarily affirming the final written decisions of the PTAB in IPR2015-01117 and IPR2016-00283 that U.S. Patent No. 8,642,012 is not unpatentable.  The IPR petitions were filed by Par Pharmaceutical, Inc. and Lupin Pharmaceuticals, Inc., respectively.  The ’012 patent is owned by L&P Client Horizon Therapeutics, LLC and directed at its Ravicti®drug.  L&P lawyer Matt Phillips assisted with the IPRs and the appeal.